Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which beat the an

- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, pr

Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compa

Allarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory

Allarity Therapeutics is now poised to run its DRP ® testing in-house in a CLIA-certified laboratory

Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sec

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2

Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until A

Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript

Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market

Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (AT

The poster outlines the scientific background, study design, and clinical rationale for the Company&

Principal Investigator Kathleen N. Moore, M.D.

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy an

Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.17) per share which beat the an

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast T

TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDA

Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting

Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting

TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NA

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy an

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which met the ana

Strengthened financial position through disciplined cost management, with a year-end 2025 cash posit

Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) is expected to be posting its results before

Allarity Therapeutics, Inc. (NASDAQ: ALLR - Get Free Report) was the recipient of a large decline in

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2

Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian C

Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Ce

This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's

U.S. stock futures were swinging between gains and losses on Tuesday after a mixed session on Monday